Hopes for Mounjaro in the obesity space

19 October 2022
eli_lilly_science_large

The recent European Commission’s (EC) approval of Eli Lilly’s (NYSE: LLY) Mounjaro (tirzepatide) for treating type 2 diabetes (T2D) is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treat Published diseases, including obesity.

The drug has the potential to address a key unmet need by introducing a new mechanism of action into the T2D space - which is expected to reach $91.6 billion by 2029 as projected by data and analytics company GlobalData in 2021 - and potentially the obesity space.

Mounjaro is a glucagon like peptide 1 (GLP-1) receptor agonist, similar to many other treatments for T2D and obesity on the market, including Novo Nordisk’s (NOV: N) Wegovy (semaglutide), the first GLP-1 agonist approved for weight loss, and the firm’s Saxenda (liraglutide).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical